Back to your search result

Description

As one of the leading causes of drug candidate attrition, toxicity research is receiving more attention, especially in the search of sensitive, organ-specific toxicity biomarkers. In pharmaceutical and chemical industries, renal function is routinely assessed during toxicity evaluations. The importance of the kidney as a central detoxification organ leads to a high exposure of renal tissue to drugs, reactive metabolites, and environmental compounds. Traditional markers for assessing renal toxicity, such as blood urea nitrogen (BUN) and serum creatinine, are insensitive and non-specific. For improved, non-invasive detection of acute nephrotoxicity, a panel of novel urinary kidney biomarkers has been identified and validated for preclinical studies in relevant animal species. MILLIPLEX(R) Canine Kidney Toxicity Panel 2 is a 4-plex kit to be used for the simultaneous quantification of any combination of the following analytes in canine urine samples: Albumin*, beta-2-microglobulin (B2M)*, Trefoil Factor 3 (TFF-3)*, Retinol Binding Protein 4 (RBP4)*. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate. *Urinary albumin, B2M, TFF-3 and RBP4 are biomarkers listed in the Predictive Safety Testing Consortium (PSTC) project pipeline which have a strong translational role in drug safety testing. The Luminex(R) xMAP(R) platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume. Panel Type: Toxicity